Lexaria Bioscience Signs 10 year deal with Hill Street

Your content goes here. Edit or remove this text inline or in the module Content settings. You can also style every aspect of this content in the module Design settings and even apply custom CSS to this text in the module Advanced settings.

Lexaria Bioscience (CSE: LXX) President and CEO Chris Bunka joined Steve Darling from Proactive Investors Vancouver to talk about the company agreeing to a 10-year deal that will see Hill Street using Leaxraia’s DehydraTech technology to infuse beverages and other products. 

Bunka telling Proactive how the deal will work and what markets this new deal will open to both companies.